DuFresne New CEO at Ischemix

Xconomy Boston — 

Ischemix, a Maynard, MA-based developer of drugs intended to prevent tissue damage that occurs after heart attacks and other cardiac events, says that it has appointed board member Robert “Duffy” DuFresne to be its new CEO. He will replace former chief executive Reinier Beeuwkes, who is remaining president and chairman of the company. By the middle of 2009, Ischemix expects to begin mid-stage clinical trials of its lead drug for preventing ischemia-reperfusion injury. Xconomy contributor David Stipp wrote last year that the drug, dubbed “CMX-2043,” could draw big drug companies to startup in search of rights to the treatment.